Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
View/ Open
Date
2018-10Author
Athauda, A
Watkins, D
Mohammed, K
Chau, I
Starling, N
Rao, S
Tait, D
Aitken, K
Cunningham, D
Type
Journal Article
Metadata
Show full item recordAbstract
Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and outcomes of patients treated with either cisplatin or carboplatin based CRT at our institution.Materials and methods This is a retrospective analysis of patients with localised OG cancer undergoing CRT with cisplatin/fluoropyrimidine (CX/F) or carboplatin/fluoropyrimidine (CarboX/F) between January 2001 and December 2014.Results A total of 91 eligible patients were included. Median age was 65 years (IQR=57-75) for CX/F and 77 years (IQR=69-80) for CarboX/F. Adenocarcinoma histology and Charlson comorbidity index were higher in the CarboX/F group. Endoscopic complete response (CR) was achieved in 64% of CX/F group and 48% of CarboX/F group (p=0.19). The median PFS for CX/F was 31.0 months (95%CI=18.2-NE) vs. 18.7 months for CarboX/F (95%CI=13.5-30.4; HR=1.49, p=0.21).Conclusion Despite significant differences in baseline clinical characteristics, patients treated with carboplatin CRT demonstrated no significant difference in PFS or endoscopic CR rate, compared to those treated with cisplatin.
Collections
Subject
Esophagogastric Junction
Humans
Adenocarcinoma
Carcinoma, Squamous Cell
Esophageal Neoplasms
Stomach Neoplasms
Cisplatin
Paclitaxel
Carboplatin
Fluorouracil
Antineoplastic Combined Chemotherapy Protocols
Prognosis
Survival Rate
Retrospective Studies
Follow-Up Studies
Aged
Middle Aged
Female
Male
Chemoradiotherapy
Tertiary Care Centers
Research team
Gastrointestinal Cancers Clinical Trials
Medicine (RMH Smith Cunningham)
Language
eng
Date accepted
2018-09-04
License start date
2018-10
Citation
Anticancer research, 2018, 38 (10), pp. 5943 - 5949